| Axial spondyloarthritis | Univariate | Final model | ||
| HR | p | HR | p | |
| Gender, women versus men | 2.29 (1.22 to 4.29) | 0.01 | 1.85 (0.81 to 4.25) | 0.15 |
| Age, years | 0.98 (0.96 to 1.02) | 0.15 | 0.99 (0.95 to 1.03) | 0.6 |
| Methotrexate use, no versus yes | 1.36 (0.68 to 2.86) | 0.4 | – | – |
| Patient’s global score, mm | 1.02 (1.01 to 1.03) | 0.003 | 1.02 (1.01 to 1.04) | 0.009 |
| BASDAI | 1.02 (1.01 to 1.04) | 0.003 | – | – |
| ASDAS | 1.09 (0.76 to 1.56) | 0.6 | – | – |
| CRP, mg/L | 0.92 (0.84 to 1.01) | 0.08 | 0.90 (0.81 to 1.00) | 0.04 |
| Longer CT-P13 interval, weeks | 0.69 (0.54 to 0.88) | 0.002 | – | – |
| Higher CT-P13 dose, mg/kg | 1.66 (1.22 to 2.26) | 0.001 | 1.63 (1.06 to 2.51) | 0.03 |
| INX start year 2000–2007 versus 2008–2015 | 0.32 (0.16 to 0.65) | 0.002 | – | – |
| Number of comorbidities | 0.67 (0.34 to 1.39) | 0.3 | – | – |
Results from univariable and multivariable Cox regression analyses stratified by diagnosis.
Cox regression analyses stratified by diagnosis. Numbers are HR (95% CI). p Values <0.1 are marked with bold and the corresponding variables were included in multivariable analysis. Age and gender remained in the model irrespective of p value.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; DAS28, 28 Joint Disease Activity Score.